Citations

Showing 10 of 108094 citations.

First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma
Chakrabarti, Sakti , Paripati, Harshita, Ross, Helen J. , Yoon, Harry H. , Paripati, Harshita R, Dong, Haidong , Chakrabarti, Sakti

Mayo Clinic

The Oncologist | April 19, 2018 | Volume: 23 | Issue: 7 | Pages: 840-843

10.1634/theoncologist.2017-0561 | PMID 29674442 Get It

Abstract Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma. This report describes the exceptional response of two patients who received ramucirumab plus paclitaxel after progressive disease on pembrolizumab. This early clinical observation suggests that the sequence of administration of PD-1 blockade and chemotherapy may be important in this disease.
Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience
Jin, Zhaohui , Sanhueza, Cristobal T., Nagorney, David M. , Mara, Kristin C. , Harmsen, William, Smyrk, Thomas C. , Grothey, Axel, Johnson, Benny, Harmsen, William C, Hubbard, Joleen M. , Mara, Kristin C , Jin, Zhaohui , Johnson, Benny , Larson, David W.

Mayo Clinic

The Oncologist | April 19, 2018 | Volume: 23 | Issue: 9 | Pages: 1083-1091

10.1634/theoncologist.2017-0289 | PMID 29674439 Get It

Abstract Background Deficiencies in the DNA mismatch repair system cause errors during DNA replication, which in turn give rise to microsatellite instability (MSI). The impact of MSI on survival in metastatic colorectal cancer (mCRC) is unclear. This cohort study aims to investigate the prognostic and predictive value of MSI in mCRC prior to the immune therapy era. Materials and Methods A total of 75 MSI-high (MSI-H) mCRC patients (pts) and 75 matched (age, gender, disease sidedness, metachronous/synchronous) microsatellite-stable (MSS) mCRC pts were identified from 1,268 mCRC pts who had MSI/mismatch repair test results at Mayo Clinic Rochester between January 1992 and July 2016. A retrospective review was conducted by using data from electronic medical records. Statistical analyses utilized the Kaplan-Meier method, log-rank test, and Cox proportional hazards models. Results The MSS group was well matched to the MSI-H group based on age, gender, location, and chronicity of metastatic disease. MSI-H mCRC pts had earlier disease recurrence (median time from initial diagnosis to metastatic disease diagnosis, MSI-H group 12.9 vs. MSS group 20.9 months, p = .034). Median overall survival (OS) was 28.1 and 37.4 months for MSI-H and MSS pts, respectively (p = .99). In total, 94.7% of MSI-H pts and 98.7% of MSS pts had fluoropyrimidine-based chemotherapy for metastatic disease, and there was no difference in OS between these two groups (32.3 vs. 37.4 months, p = .91). Forty-three MSI-H and thirty-nine MSS pts had metastasectomy and/or ablation of metastases (p = .51) with longer median OS compared with pts without metastasectomy (MSI-H: 82.0 vs. 13.9, p < .001; MSS: 69.9 vs. 19.7, p < .001). Age <65 years, BRAF wild type, and metastasectomy were associated with better OS in univariate analysis. Only metastasectomy remained statistically significant in multivariate analysis (p < .001). Conclusion In mCRC, patients with MSI-H tumors have similar, but numerically shorter, median overall survival compared with those with MSS tumors. In both groups, metastasectomy and ablation of metastatic disease should be considered to optimize OS. Implications for Practice This study clearly demonstrated the survival benefits that aggressive metastasectomy provides in selected microsatellite instability-high metastatic colorectal cancer patients. This could be meaningful practice-changing information that has been long awaited.
Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis
Kleinstern, Geffen , Camp, Nicola J. , Goldin, Lynn R. , Vachon, Celine M. , Vajdic, Claire M. , Sanjosé, Sílvia de, Weinberg, J. Brice , Benavente, Yolanda , Casabonne, Delphine, Liebow, Mark , Nieters, Alexandra, Hjalgrim, Henrik , Melbye, Mads , Glimelius, Bengt , Adami, Hans‐Olov , Brennan, Paul , McKay, James , Cocco, Pier Luigi, Call, Timothy G. , Hanson, Curtis A. , Robinson, Dennis P. , Chaffee, Kari G. , Brooks‐Wilson, Angela , Monnereau, Alain, Clavel, Jacqueline , Glenn, Martha, Curtin, Karen , Conde, Lucía , Bracci, Paige M. , Morton, Lindsay M. , Severson, Richard K., Chanock, Stephen J., Spinelli, John J., Johnston, James B. , Rothman, Nathaniel , Skibola, Christine F., Leis, José F., Smedby, Karin E. , Berndt, Sonja I. , Caporaso, Neil E., Rabe, Kari G. , Cocco, Pierluigi , Monnereau, Alain , Norman, Aaron D. , Hanson, Curtis, Robinson, Dennis, Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Morton, Lindsay M , Clavel, Jacqueline , Vachon, Celine M. , Casabonne, Delphine , Boffetta, Paolo , Maynadié, Marc , Shanafelt, Tait D. , Cozen, Wendy , Rothman, Nathaniel , Kay, Neil E. , Cerhan, James R. , Slager, Susan L.

Mayo Clinic

Blood | April 19, 2018 | Volume: 131 | Issue: 23 | Pages: 2541-2551

10.1182/blood-2017-11-814608 | PMID 29674426 Get It

Key Points PRS, based on the known CLL loci, predicts CLL risk with high discrimination. This PRS predicts risk of monoclonal B-cell lymphocytosis, a precursor to CLL and a condition that has clinical impact beyond risk for CLL.
Prognostic Utility of Stress Testing and Cardiac Biomarkers in Menopausal Women at Low to Intermediate Risk for Coronary ARTery Disease (SMART Study): 5-Year Outcome
Ball, Caroline , Hagen, Mary E., Eifert-Rain, Susan, Wilansky, Susan , Castelló, Ramón, Pellikka, Patricia A. , Best, Patricia J.M. , Abdelmoneim, Sahar S. , Ball, Caroline A, Mantovani, Francesca , Pellikka, Patricia A , Mulvagh, Sharon L.

Mayo Clinic

Journal of Women's Health | April 19, 2018 | Volume: 27 | Issue: 5 | Pages: 542-551

10.1089/jwh.2017.6506 | PMID 29672210 Get It

Background: In women with low to intermediate risk of coronary artery disease (CAD), prognostic detection strategies have been controversial. We present the follow-up data of the SMART trial in peri/postmenopausal women at low to intermediate risk of CAD. Objectives: To determine the value of contrast stress echocardiography (CSE), stress electrocardiogram (sECG), and serum biomarkers for prediction of cardiovascular events (CE) in peri/postmenopausal women at low to intermediate risk of CAD. Materials and Methods: From January 2004 to August 2007, 400 peri/postmenopausal women were prospectively enrolled. All women had detailed risk factor assessment, and underwent simultaneous CSE (Definity ® , Lantheus Medical Imaging) and sECG. Laboratories included brain natriuretic peptide (BNP), atrial natriuretic peptide, endothelin, and high sensitivity C-reactive protein. Wall motion score index was based on a 16-segment model. Abnormal CSE was defined as new or worsening wall motion abnormality at stress, while abnormal sECG was ≥1 mm horizontal/downsloping ST segment depression/elevation (80 mseconds duration). Self-reported outcome data were collected from a mailed Women's Heart Clinic Questionnaire. CE outcomes included all-cause mortality, nonfatal myocardial infarction (MI), heart failure, chest pain hospitalization or development of typical angina (CP), and revascularization (REVASC). Adjusted Cox proportional hazard ratios (HR; 95% confidence intervals) were reported. Results: A total of 366 women (54.4 ± 5.5 years, Framingham risk 6.5% ± 4.4%) completed simultaneous CSE and sECG. Forty-two (11.5%) had abnormal CSE, while sECG was abnormal in 22 (6%) women. Follow-up (4.4 ± 1.2 years) was available in 315/366 (86%) women (78% exercise-CSE, 22% dobutamine-CSE). In those who completed follow-up, CSE was abnormal in 33 women (10.5%) and sECG was abnormal in 21 (6.7%). In 33 women with abnormal CSE, sECG was abnormal in 7 (21.2%) and normal in 26 (79%), p = 0.0004. CE occurred in 27 (8.6%) women: 8 all-cause mortality, 2 nonfatal MI, 13 CP, and 4 REVASC. CE occurred in 21% versus 7% of women with abnormal versus normal CSE, p = 0.014 and 38% versus 6% of women with abnormal versus normal sECG, p < 0.0001. Rest BNP was higher in women with CE versus those without ( p = 0.018). Abnormal sECG and abnormal CSE were associated with CE, while only abnormal sECG was an independent predictor of CE (adjusted HR 10.3 [1.9–61.4], p = 0.007). Of the laboratory results, only BNP was associated with CE (adjusted HR 2.9 [1.1–7.3], p = 0.028). Conclusions: sECG and rest BNP were independent predictors of subsequent CE within 5 years in peri/postmenopausal women at low to intermediate risk of CAD.
Trends in Enteral Access Placement Among Patients With Oral Clefts: Evaluation of 46 617 Patient Admissions
Boonipat, Thanapoom , Adams, Nicholas S., Shoemaker, Allen, Mann, Robert J., Polley, John W. , Girotto, John A.

Mayo Clinic

The Cleft Palate Craniofacial Journal | April 19, 2018 | Volume: 56 | Issue: 1 | Pages: 21-30

10.1177/1055665618771425 | PMID 29672164 Get It

Objective: It is well known that patients with oral clefts have challenges with feeding. Enteral feeding access, in the form of gastrostomy, is often utilized to supplement or replace oral intake. Although commonly performed, these procedures have reported complication rates as high as 83%. We intend to discover rates of enteral access in patients with oral clefts and report-related outcomes. Design: The Healthcare Cost Utilization Project Kids’ Inpatient Database from 2000 to 2012 was analyzed using patients with oral clefts and enteral access procedures. The χ 2 test was used for univariate analyses of proportions, and linear regression was used to analyze trends. Multivariate logistic regression was used to analyze odds ratios. Results: Of the 46 617 patient admissions included, 14.6% had isolated cleft lip (CL), 51.7% cleft lip and palate (CLP), and 43.7% isolated cleft palate. The rates of enteral access in the oral cleft population increased from 3.7% in 2000 to 5.8% in 2012 ( P < .001). Increased rates were identified in patients with ( P = .019) and without ( P < .001) complex conditions. A significant increase in the rate of enteral access was seen in patients with CLP ( P < .001) and isolated cleft palate ( P < .001). No difference was seen in the isolated CL group ( P = .096). Patients with complex conditions were at a 4.4-fold increased risk and those admitted to urban, teaching hospitals were at a 4.7-fold risk of enteral access placement. Conclusions: The rates for enteral feeding access increased significantly from 2000 to 2012. The reasons for the increased incidence are unclear. Invasive enteral access procedures have been shown to have a multitude of complications. Careful patient selection should be done before placement of invasive enteral access.
Neuropsychological and Behavioral Outcomes after Exposure of Young Children to Procedures Requiring General Anesthesia
Zaccariello, Michael J. , Katusic, Slavica K., Schroeder, Darrell R. , Hanson, Andrew C. , Schulte, Phillip J. , Buenvenida, Shonie L., Gleich, Stephen J. , Wilder, Robert T., Hu, Danqing , Voigt, Robert G. , Paule, Merle G. , Chelonis, John J. , Flick, Randall P., Schroeder, Darrell , Warner, David O. , Šprung, Juraj

Mayo Clinic

Anesthesiology | April 19, 2018 | Volume: 129 | Issue: 1 | Pages: 89-105

10.1097/aln.0000000000002232 | PMID 29672337 Get It

Abstract Background Few studies of how exposure of children to anesthesia may affect neurodevelopment employ comprehensive neuropsychological assessments. This study tested the hypothesis that exposure to multiple, but not single, procedures requiring anesthesia before age 3 yr is associated with adverse neurodevelopmental outcomes. Methods Unexposed, singly exposed, and multiply exposed children born in Olmsted County, Minnesota, from 1994 to 2007 were sampled using a propensity-guided approach and underwent neuropsychological testing at ages 8 to 12 or 15 to 20 yr. The primary outcome was the Full-Scale intelligence quotient standard score of the Wechsler Abbreviated Scale of Intelligence. Secondary outcomes included individual domains from a comprehensive neuropsychological assessment and parent reports. Results In total, 997 children completed testing (411, 380, and 206 unexposed, singly exposed, and multiply exposed, respectively). The primary outcome of intelligence quotient did not differ significantly according to exposure status; multiply exposed and singly exposed children scoring 1.3 points (95% CI, −3.8 to 1.2; P = 0.32) and 0.5 points (95% CI, −2.8 to 1.9; P = 0.70) lower than unexposed children, respectively. For secondary outcomes, processing speed and fine motor abilities were decreased in multiply but not singly exposed children; other domains did not differ. The parents of multiply exposed children reported increased problems related to executive function, behavior, and reading. Conclusions Anesthesia exposure before age 3 yr was not associated with deficits in the primary outcome of general intelligence. Although secondary outcomes must be interpreted cautiously, they suggest the hypothesis that multiple, but not single, exposures are associated with a pattern of changes in specific neuropsychological domains that is associated with behavioral and learning difficulties.
Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer
Tamura, Koji , Hata, Tatsuo , Suenaga, Masaya, Abe, Toshiya , Macgregor-Das, Anne , Borges, Michael , Wolfgang, Christopher L. , Weiss, Matthew J. , He, Jin , Petersen, Gloria M. , Gallinger, Steven , Rustgi, Anil K. , Zogopoulos, George , Potash, James B. , McCombie, W. Richard , Zandi, Peter P. , Pirooznia, Mehdi , Kramer, Melissa , Parla, Jennifer, Eshleman, James R. , Roberts, Nicholas J. , Hruban, Ralph H. , Pirooznia, Mehdi , Tamura, Koji , Yu, Jun , Shindo, Koji , Canto, Marcia Irene , Syngal, Sapna , Brand, Randall E. , Olson, Sara H. , Stoffel, Elena M. , Coté, Michele L. , Goes, Fernando , Klein, Alison P. , Goggins, Michael

Mayo Clinic

Proceedings of the National Academy of Sciences | April 19, 2018 | Volume: 115 | Issue: 18 | Pages: 4767-4772

10.1073/pnas.1720588115 | PMID 29669919 Get It

Significance Much of the inherited susceptibility to pancreatic cancer remains unexplained. Germline variants that cause protein misfolding and impaired secretion of pancreatic enzymes such as CPA1 (encoding carboxypeptidase A1) can cause pancreatic acinar cell endoplasmic reticulum (ER) stress. We investigated the hypothesis that pancreatic cancer could arise from germline variants in genes encoding pancreatic secretory enzymes that induce pancreatic acinar cell stress. We find ∼1% of 1,579 patients with pancreatic cancer vs. 1 of 2,012 controls have germline variants in the genes encoding CPA1 and CPB1 (carboxypeptidase B1) that impair secretion of its protein product and induce ER stress. These findings implicate pancreatic acinar cell stress as a mechanism of pancreatic cancer susceptibility.
Neuro-oncologists have spoken – the role of bevacizumab in the inpatient setting. A clinical and economic conundrum
Sharma, Akanksha , Low, Justin , Mrugala, Maciej , Low, Justin T

Mayo Clinic

Neuro-Oncology Practice | April 19, 2018 | Volume: 6 | Issue: 1 | Pages: 30-36

10.1093/nop/npy011 | PMID 31385984 Get It

Abstract Background Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), a key player in tumor angiogenesis. The drug can halt tumor progression, treat radiation necrosis, and reduce peritumoral edema. Although it does not increase overall survival, bevacizumab can improve progression-free survival and quality of life. In many countries, bevacizumab use in the inpatient setting is restricted due to its significant cost. Here, we explore attitudes towards the use of bevacizumab amidst practitioners treating brain tumors and assess ease of accessing the drug in the inpatient setting. Design/Methods A 10-question survey querying practitioners’ opinions of inpatient bevacizumab utility and its availability was distributed to the membership of the Society of Neuro-Oncology in July 2016. Results Eighty-seven percent felt that there was a role for bevacizumab in the inpatient setting, and 69% reported favorable experiences with bevacizumab use. However, 40% encountered difficulty in obtaining approval for inpatient use. We present two contrasting clinical cases that highlight favorable and unfavorable outcomes when bevacizumab use was and was not permitted, respectively. Conclusions In this sample of neuro-oncology practitioners, there is general consensus that bevacizumab plays an important role in the inpatient treatment of brain tumors. In light of ongoing barriers to inpatient bevacizumab use due to cost concerns, these data motivate the creation of standardized policies for inpatient bevacizumab use that balances its important role in improving quality of life with financial considerations.
Allogeneic Stem Cell Transplantation Alone is Unlikely to Provide the HIV-1 Cure
Cummins, Nathan W. , Badley, Andrew D.

Mayo Clinic

Future Virology | April 19, 2018 | Volume: 13 | Issue: 5 | Pages: 307-308

10.2217/fvl-2018-0005 Get It

Empowering genomic medicine by establishing critical sequencing result data flows: the eMERGE example
Aronson, Samuel , Babb, Lawrence , Ames, Darren C., Gibbs, Richard A. , Connelly, John, Marsolo, Keith , Hartzler, Andrea L. , Liang, Wayne H. , Ralston, James D. , Devine, Emily Beth , Murphy, Shawn N. , Freimuth, Robert R. , Rasmussen, Luke V. , Peterson, Josh F. , Robinson, Jamie R. , Wiley, Ken, Taylor, Casey Overby , Group, eMERGE Network EHRI Working, Caraballo, Pedro J. , Babb, Lawrence , Rasmussen, Luke V , Freimuth, Robert R , Venner, Eric , Weng, Chunhua , Williams, Marc S , Chute, Christopher G. , Kullo, Iftikhar J. , Wehbe, Firas , Group, eMERGE Network EHRI Working, Peterson, Josh F

Mayo Clinic

Journal of the American Medical Informatics Association | April 19, 2018 | Volume: 25 | Issue: 10 | Pages: 1375-1381

10.1093/jamia/ocy051 | PMID 29860405 Get It

AbstractThe eMERGE Network is establishing methods for electronic transmittal of patient genetic test results from laboratories to healthcare providers across organizational boundaries. We surveyed the capabilities and needs of different network participants, established a common transfer format, and implemented transfer mechanisms based on this format. The interfaces we created are examples of the connectivity that must be instantiated before electronic genetic and genomic clinical decision support can be effectively built at the point of care. This work serves as a case example for both standards bodies and other organizations working to build the infrastructure required to provide better electronic clinical decision support for clinicians.